OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA). Read More
Recent Posts
Europe Faces Most Difficult Moment in Bid to Avoid Split With US
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Hastings Racecourse in Vancouver to shut down permanently, operator says
Russia’s Vital Oil Trade With India Is Down, But Not Out
Copper Quest Closes $1,927,000 Private Placement
This TSX stock was up 17% this week and it could gain another 36%, analysts say
AMC Entertainment Holdings, Inc. Transfers the Majority of its Equity Investment in Hycroft Mining Holding Corporation to Sprott Mining for a Net Consideration of $24.1 million
Guardian Capital Announces Estimated 2025 Annual Non-Cash Distributions for Guardian Capital ETFs
Emera Renews At-The-Market Equity Program
CRA warns of ‘aggressive tax schemes’ involving critical illness insurance
